On Friday, Exane BNP Paribas (OTC:BNPQY) adjusted its price target for Clorox shares (NYSE:NYSE:CLX), increasing it to $140 from the previous $134, while maintaining an Underperform rating on the stock. The adjustment followed a positive sell-side meeting with Clorox's CEO and CFO in New York City. The firm acknowledged the management's confidence and the strategic measures being taken to spur growth, despite maintaining a cautious stance on the company's financial estimates.
According to Exane BNP Paribas, Clorox management displayed a renewed sense of confidence and urgency in accelerating the company's growth. This comes after a period marked by various challenges, including the COVID-19 pandemic, fluctuating commodity prices, and a cyberattack. The firm noted that the management's multi-year investments are beginning to provide better visibility for the future.
However, Exane BNP Paribas expressed concern over several factors impacting Clorox. The analyst pointed out that growth in the company's category has slowed, with consumer demand becoming more uncertain.
Moreover, Clorox is at a heightened risk of consumers trading down to cheaper alternatives. The gross margin percentage story is considered to have fully unfolded, and the fiscal year 2025 guidance appears optimistic, assuming an acceleration in volume growth and market share gains that the analyst finds questionable.
The firm also finds Clorox's stock valuation to be potentially overstretched, as it has been re-rated to 25 times its price-to-earnings (P/E) ratio. Despite the management's capable leadership and sound strategy, Exane BNP Paribas remains cautious about the achievability of Clorox's financial estimates and the company's growth prospects in the current consumer environment.
In other recent news, Clorox has been experiencing a series of positive developments. The company reported its seventh consecutive quarter of margin expansion, despite the challenges from a past cyberattack. Both financial firms Jefferies and Citi have raised their price targets for Clorox, with Jefferies increasing its target to $174 from $151 and Citi adjusting its target to $170 from $165. Both firms maintain a neutral stance on Clorox's stock.
Clorox has also been making strides in product development, with CloroxPro expanding the Clorox EcoClean line by introducing plant-based Disinfecting Wipes. These eco-friendly wipes combat 99.9% of germs, including common cold, flu viruses, norovirus, and COVID-19.
Furthermore, Clorox has shown resilience in the face of challenges, maintaining stable organic sales and outlining strategies to tackle anticipated consumer pressures and competitive activity in fiscal year 2025. These recent developments underscore Clorox's commitment to growth and recovery.
InvestingPro Insights
In the context of Exane BNP Paribas's recent price target adjustment for Clorox (NYSE:CLX), it's worth noting that Clorox has demonstrated a strong commitment to shareholder returns, having raised its dividend for an impressive 47 consecutive years, according to InvestingPro Tips. This signals a robust track record that income-focused investors may find attractive.
Moreover, despite the challenges outlined by Exane BNP Paribas, analysts have revised their earnings upwards for the upcoming period, suggesting that there may be more optimism around the company's financial performance than initially perceived.
From a data perspective, Clorox's market capitalization stands at $20.41 billion, with a high P/E ratio of 73.05, which contrasts with the near-term earnings growth and results in a more moderate adjusted P/E ratio of 34.15 for the last twelve months as of Q4 2024. The company's revenue has seen a slight downturn with a -4.01% change over the same period.
Nevertheless, Clorox has maintained a strong gross profit margin of 43.21%, indicating effective cost management relative to its revenues. Investors may also take note of the company's dividend yield of 2.96%, which complements the aforementioned positive dividend growth trend.
For those seeking further insights and additional InvestingPro Tips for Clorox, there are 15 listed on the platform, providing a more comprehensive analysis that could aid in making informed investment decisions. The InvestingPro product offers a detailed view of these metrics and more, which can be accessed at https://www.investing.com/pro/CLX.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.